Twist Bioscience (NASDAQ:TWST) CEO Emily Leproust Sells 41,570 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 41,570 shares of Twist Bioscience stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $151.98, for a total transaction of $6,317,808.60. Following the completion of the transaction, the chief executive officer directly owned 770,729 shares of the company’s stock, valued at $117,135,393.42. The trade was a 5.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Stock Up 2.0%

Shares of NASDAQ TWST opened at $153.10 on Friday. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $155.44. The firm’s 50-day moving average price is $105.88 and its 200-day moving average price is $73.35. The stock has a market capitalization of $9.60 billion, a price-to-earnings ratio of -68.96 and a beta of 2.14.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The company had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The company’s revenue was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.33 EPS. On average, equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TWST has been the subject of several recent analyst reports. Piper Sandler lifted their price objective on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. TD Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 3rd. Evercore cut shares of Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target for the company. in a research note on Monday, July 6th. Leerink Partners set a $110.00 price target on shares of Twist Bioscience in a report on Thursday, July 16th. Finally, Robert W. Baird increased their price objective on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $98.30.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Corient Private Wealth LP purchased a new position in Twist Bioscience during the 2nd quarter worth $2,226,000. Amundi bought a new position in shares of Twist Bioscience during the 2nd quarter worth $252,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Twist Bioscience during the 2nd quarter worth $1,640,000. California State Teachers Retirement System increased its stake in shares of Twist Bioscience by 10,945.7% during the second quarter. California State Teachers Retirement System now owns 7,770,424 shares of the company’s stock valued at $799,421,000 after buying an additional 7,700,076 shares during the period. Finally, AlphaGrep UK Ltd bought a new stake in shares of Twist Bioscience in the second quarter valued at about $229,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.